n(4)-hydroxycytidine has been researched along with molnupiravir in 13 studies
| Studies (n(4)-hydroxycytidine) | Trials (n(4)-hydroxycytidine) | Recent Studies (post-2010) (n(4)-hydroxycytidine) | Studies (molnupiravir) | Trials (molnupiravir) | Recent Studies (post-2010) (molnupiravir) |
|---|---|---|---|---|---|
| 42 | 1 | 32 | 264 | 17 | 259 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 13 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hampton, T | 1 |
| Agostini, ML; Baric, RS; Bluemling, GR; Brown, AJ; Chappell, JD; Denison, MR; Dinnon, KH; George, AS; Graham, RL; Harcourt, J; Hill, CS; Hughes, TM; Kolykhalov, AA; Leist, SR; Lu, X; Montgomery, SA; Natchus, MG; Painter, G; Pruijssers, AJ; Saindane, M; Schäfer, A; Sheahan, TP; Sims, AC; Stevens, LJ; Swanstrom, R; Tamin, A; Thornburg, NJ; Zhou, S | 1 |
| Gordon, CJ; Götte, M; Schinazi, RF; Tchesnokov, EP | 1 |
| Hughes, C; Lewis, P; Warren, S; Waters, MD; Zhang, F | 1 |
| André, E; Chiu, W; De Jonghe, S; Jochmans, D; Leyssen, P; Maes, P; Neyts, J; Raymenants, J; Slechten, B; Vangeel, L | 1 |
| Schinazi, RF; Swanstrom, R | 1 |
| Amara, A; Bullock, K; Dickinson, L; Else, L; Ewings, S; FitzGerald, R; Fletcher, T; Greenhalf, W; Griffiths, G; Hale, C; Holman, W; Khoo, S; Lavelle-Langham, L; Lyon, R; Painter, W; Penchala, SD; Reynolds, H; Shaw, V; Walker, L | 1 |
| Cao, R; Chen, X; Dai, Q; Guo, X; Li, W; Li, Y; Liu, M; Wang, Z; Yan, Y; Yang, X; Zhong, W | 1 |
| Dobrovolsky, VN; McKinzie, PB; Miranda, JA; Revollo, JR | 1 |
| Bluemling, GR; Brasel, T; Comer, JE; De La Rosa, A; Freiberg, AN; Kolykhalov, AA; Lockwood, M; Mao, S; Mulangu, S; Natchus, MG; Painter, GR; Painter, W | 1 |
| Ahmed, S; Hirao, Y; Kato, S; Kawanishi, S; Kobayashi, H; Mori, Y; Murata, M; Oikawa, S | 1 |
| Ahn, SB; An, YJ; Cho, JH; Choi, ER; Choi, SM; Jang, Y; Kim, M; Nam, YE; Seo, EW | 1 |
| Ahmed, A; Bhardwaj, M; Dhiman, S; Gour, A; Khajuria, P; Manhas, D; Mukherjee, D; Nandi, U; Wazir, P | 1 |
1 review(s) available for n(4)-hydroxycytidine and molnupiravir
| Article | Year |
|---|---|
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Deoxyuridine; DNA Damage; Genome, Human; Humans; Hydroxylamines; Mutagenesis; Nucleosides; Pyrazines; Ribavirin; SARS-CoV-2 | 2022 |
1 trial(s) available for n(4)-hydroxycytidine and molnupiravir
| Article | Year |
|---|---|
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Nucleosides; Parents; Prodrugs; SARS-CoV-2 | 2022 |
11 other study(ies) available for n(4)-hydroxycytidine and molnupiravir
| Article | Year |
|---|---|
New Flu Antiviral Candidate May Thwart Drug Resistance.
Topics: Animals; Antiviral Agents; Cytidine; Disease Models, Animal; Drug Resistance, Viral; Humans; Hydroxylamines; Influenza, Human; Macaca; Ribonucleosides | 2020 |
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibiotic Prophylaxis; Antiviral Agents; Betacoronavirus; Cell Line; Coronavirus Infections; COVID-19; Cytidine; Disease Models, Animal; Drug Resistance, Viral; Humans; Hydroxylamines; Lung; Mice; Mice, Inbred C57BL; Middle East Respiratory Syndrome Coronavirus; Models, Molecular; Mutation; Pandemics; Pneumonia, Viral; Primary Cell Culture; Random Allocation; Respiratory System; Ribonucleosides; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Virus Replication | 2020 |
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Mutagenesis; Point Mutation; RNA, Viral; SARS-CoV-2 | 2021 |
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Topics: Adenosine; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Microbial Sensitivity Tests; Nitriles; Proline; RNA-Dependent RNA Polymerase; SARS-CoV-2; Vero Cells; Virus Replication | 2022 |
Lethal mutagenesis as an antiviral strategy.
Topics: Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; DNA; Evolution, Molecular; Genome, Viral; Humans; Hydroxylamines; Mutagenesis; Mutagenicity Tests; Phosphorylation; Ribonucleosides; RNA Virus Infections; RNA Viruses; RNA, Viral; SARS-CoV-2 | 2022 |
Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo.
Topics: Animals; Antigens, Viral; Antiviral Agents; Child, Preschool; COVID-19; Cytidine; Enterovirus; Enterovirus A, Human; Enterovirus Infections; Humans; Hydroxylamines; Mice; Mice, Inbred ICR | 2022 |
Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing.
Topics: Animals; COVID-19; DNA; Escherichia coli; Humans; Mammals; Mice; Mutagens; RNA, Viral; SARS-CoV-2 | 2022 |
The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N
Topics: Animals; Antiviral Agents; Ebolavirus; Hemorrhagic Fever, Ebola; Mice; Ribonucleosides | 2023 |
Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
Topics: Antiviral Agents; COVID-19; DNA Damage; Humans; Hydrogen Peroxide; Hydroxylamines; Oxidative Stress; SARS-CoV-2 | 2023 |
Synthesis and biological evaluation of new β-D-N
Topics: Antiviral Agents; COVID-19; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; SARS-CoV-2; Virus Replication | 2023 |
Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment.
Topics: Animals; COVID-19; Cytidine; Hydroxylamines; Rats | 2023 |